Anemia of inflammation (AI) is common among patients with diabetic foot ulcers (DFU). This study aimed to investigate the specific relationship between inflammation indicators and anemia in patients with DFU. This cross-sectional study was carried out among patients with DFU between 2018 and 2023. Clinical data were gathered before treatment. Restricted cubic spline regression was employed to investigate the non-linear associations between inflammation and anemia. A total of 395 patients with Wagner grades 2-4 were enrolled in the study. About 63.54% of the patients with DFU had anemia which was primarily presented with normocytic hypopigmentation anemia. Elevated IL-6 levels (39.10-369 pg/ml) were significantly associated with an increased likelihood of anemia (OR = 4.84; 95% CI: 1.97-11.90). Similarly, high CRP levels (48.56-385 mg/l) were linked to a higher prevalence of anemia (OR = 5.01; 95% CI: 2.35-10.68). Furthermore, a nonlinear relationship was observed between CRP levels and anemia, suggesting that CRP values exceeding 53.889 mg/l may trigger anemia in patients with diabetic foot ulcers. Inflammation is identified as an independent risk factor for AI in patients with DFU. The inflammation indicators (CRP and IL-6) and anemia exhibit an L-shaped nonlinear correlation in patients with DFU.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633438PMC
http://dx.doi.org/10.1080/17520363.2024.2421159DOI Listing

Publication Analysis

Top Keywords

patients dfu
20
anemia patients
12
patients diabetic
12
diabetic foot
12
anemia
11
patients
9
foot ulcers
8
inflammation indicators
8
crp levels
8
dfu
6

Similar Publications

Aim: To assess the effects of several adjuvant therapies (AT) commonly used in the treatment of diabetic foot ulcers (DFU). The present meta-analysis was designed to support the development of the Italian Guidelines for the Treatment of Diabetic Foot Syndrome.

Methods: A Medline and Embase search were performed up to May 20th, 2024 collecting all RCTs including diabetic patients or reporting subgroup analyses on diabetic patients with DFU comparing AT with placebo/standard of care (SoC), with a duration of at least 12 weeks.

View Article and Find Full Text PDF

Diabetic Foot Ulcer (DFU) is a major complication of diabetes that mostly affects the lower extremities, with a high incidence and recurrence rate in approximately 15% of patients with diabetes. The complexity of diabetic wounds poses a substantial challenge for clinical recovery, underscoring the need to investigate novel therapeutic approaches. Medicinal plants have been used to treat ulcers for centuries.

View Article and Find Full Text PDF

Aims/introduction: Diabetic foot ulcer (DFU) is a prevalent complication of diabetes characterized by heightened inflammation and impaired wound-healing processes. Interleukin-37 (IL-37) is a natural suppressor of innate inflammation. Here, we aim to investigate the potential of IL-37 in enhancing the healing process of diabetic wounds.

View Article and Find Full Text PDF

Hard-to-heal wounds represent a global and growing medical and economic burden. Skin autografting is a useful treatment option but is often limited by donor site morbidity, logistical considerations, and grafting success in compromised wound beds. Combining autologous skin cell suspension (ASCS) technology with minced dermal grafts can allow for dermal elements and epithelial healing as well as closed donor sites.

View Article and Find Full Text PDF

Background: Treatment of diabetes and its complications is a primary health care expense. Up to 25% of people with diabetes will develop diabetic foot ulcers (DFUs). Removable cast walker (RCW) boots commonly prescribed for DFU treatment, promote healing, and provide offloading and wound protection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!